SK Biopharmaceuticals has signed an agreement with TerraPower Isotopes, a subsidiary of TerraPower, to secure a supply of the therapeutic radioisotope Actinium-225, addressing a critical shortage in the market. The deal, announced on August 29, marks a significant step for SK Biopharmaceuticals as it focuses on expanding its presence in the radiopharmaceutical therapy (RPT) sector.
Actinium-225, known for its potent alpha-emitting properties, is used in the treatment of various cancers, including prostate, colon, and pancreatic cancers. The first batch is expected to be delivered in October, marking the beginning of a supply chain that SK Biopharmaceuticals views as essential for its future growth.
This acquisition aligns with the company’s broader strategy unveiled last year, which emphasizes next-generation therapeutic approaches like targeted protein degradation (TPD), RPT, and cell and gene therapy (CGT). The agreement not only secures a vital raw material but also positions SK Biopharmaceuticals to further explore partnerships that could enhance its competitiveness in the RPT market.
While the deal secures a critical resource, the company will need to navigate the complexities of developing and commercializing new treatments in a field known for its high entry barriers and technical challenges.
